(Q53326961)

13 May 2018

title

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. (English)

1 reference

13 May 2018

0 references

M J Postma

1

1 reference

13 May 2018

M L Heijnen

series ordinal

2

1 reference

13 May 2018

J C Jager

series ordinal

3

1 reference

13 May 2018

publication date

1 January 2001

1 reference

13 May 2018

published in

PharmacoEconomics

1 reference

13 May 2018

volume

19

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

215-222

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200119020-00008

exact match

0 references

cites work

The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease

1 reference

12 December 2020

Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.

1 reference

12 December 2020

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

1 reference

12 December 2020

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older

1 reference

12 December 2020

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

1 reference

12 December 2020

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

12 December 2020

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

12 December 2020

Temporary increase in incidence of invasive infection due to Streptococcus pneumoniae in The Netherlands

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Discounting and health benefits

1 reference

12 December 2020

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease

1 reference

12 December 2020

Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.

1 reference

12 December 2020

Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

1 reference

12 December 2020

Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study

1 reference

12 December 2020

Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential

1 reference

12 December 2020

The pneumococcal vaccine after 15 years of use.

1 reference

12 December 2020

Economic evaluation of influenza vaccination. Assessment for The Netherlands

1 reference

12 December 2020

Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

10.2165/00019053-200119020-00008

Identifiers

DOI

1 reference

13 May 2018

Dimensions Publication ID

0 references

1 reference

13 May 2018